| 1. |
-
- 2017
-
In: Physical Review D. - 2470-0010 .- 2470-0029. ; 96:2
-
Journal article (peer-reviewed)
|
|
| 2. |
- Elhai, M, et al.
(author)
-
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
- 2019
-
In: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 78:7, s. 979-987
-
Journal article (peer-reviewed)abstract
- To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical practice.MethodsWe performed a prospective study including patients with SSc from the European Scleroderma Trials and Research (EUSTAR) network treated with rituximab and matched with untreated patients with SSc. The main outcomes measures were adverse events, skin fibrosis improvement, lung fibrosis worsening and steroids use among propensity score-matched patients treated or not with rituximab.Results254 patients were treated with rituximab, in 58% for lung and in 32% for skin involvement. After a median follow-up of 2 years, about 70% of the patients had no side effect. Comparison of treated patients with 9575 propensity-score matched patients showed that patients treated with rituximab were more likely to have skin fibrosis improvement (22.7 vs 14.03 events per 100 person-years; OR: 2.79 [1.47–5.32]; p=0.002). Treated patients did not have significantly different rates of decrease in forced vital capacity (FVC)>10% (OR: 1.03 [0.55–1.94]; p=0.93) nor in carbon monoxide diffusing capacity (DLCO) decrease. Patients having received rituximab were more prone to stop or decrease steroids (OR: 2.34 [1.56–3.53], p<0.0001). Patients treated concomitantly with mycophenolate mofetil had a trend for better outcomes as compared with patients receiving rituximab alone (delta FVC: 5.22 [0.83–9.62]; p=0.019 as compared with controls vs 3 [0.66–5.35]; p=0.012).ConclusionRituximab use was associated with a good safety profile in this large SSc-cohort. Significant change was observed on skin fibrosis, but not on lung. However, the limitation is the observational design. The potential stabilisation of lung fibrosis by rituximab has to be addressed by a randomised trial.
|
|
| 3. |
|
|
| 4. |
- Hudson, Lawrence N, et al.
(author)
-
The database of the PREDICTS (Projecting Responses of Ecological Diversity In Changing Terrestrial Systems) project
- 2017
-
In: Ecology and Evolution. - : John Wiley & Sons. - 2045-7758. ; 7:1, s. 145-188
-
Journal article (peer-reviewed)abstract
- The PREDICTS project-Projecting Responses of Ecological Diversity In Changing Terrestrial Systems (www.predicts.org.uk)-has collated from published studies a large, reasonably representative database of comparable samples of biodiversity from multiple sites that differ in the nature or intensity of human impacts relating to land use. We have used this evidence base to develop global and regional statistical models of how local biodiversity responds to these measures. We describe and make freely available this 2016 release of the database, containing more than 3.2 million records sampled at over 26,000 locations and representing over 47,000 species. We outline how the database can help in answering a range of questions in ecology and conservation biology. To our knowledge, this is the largest and most geographically and taxonomically representative database of spatial comparisons of biodiversity that has been collated to date; it will be useful to researchers and international efforts wishing to model and understand the global status of biodiversity.
|
|
| 5. |
- Becker, M, et al.
(author)
-
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
- 2019
-
In: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 78:9, s. 1242-1248
-
Journal article (peer-reviewed)abstract
- Mortality and worsening of organ function are desirable endpoints for clinical trials in systemic sclerosis (SSc). The aim of this study was to identify factors that allow enrichment of patients with these endpoints, in a population of patients from the European Scleroderma Trials and Research group database.MethodsInclusion criteria were diagnosis of diffuse SSc and follow-up over 12±3 months. Disease worsening/organ progression was fulfilled if any of the following events occurred: new renal crisis; decrease of lung or heart function; new echocardiography-suspected pulmonary hypertension or death. In total, 42 clinical parameters were chosen as predictors for the analysis by using (1) imputation of missing data on the basis of multivariate imputation and (2) least absolute shrinkage and selection operator regression.ResultsOf 1451 patients meeting the inclusion criteria, 706 had complete data on outcome parameters and were included in the analysis. Of the 42 outcome predictors, eight remained in the final regression model. There was substantial evidence for a strong association between disease progression and age, active digital ulcer (DU), lung fibrosis, muscle weakness and elevated C-reactive protein (CRP) level. Active DU, CRP elevation, lung fibrosis and muscle weakness were also associated with a significantly shorter time to disease progression. A bootstrap validation step with 10 000 repetitions successfully validated the model.ConclusionsThe use of the predictive factors presented here could enable cohort enrichment with patients at risk for overall disease worsening in SSc clinical trials.
|
|
| 6. |
|
|
| 7. |
- Sarin, Nikhil, et al.
(author)
-
Low-efficiency long gamma-ray bursts : a case study with AT2020blt
- 2022
-
In: Monthly notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 512:1, s. 1391-1399
-
Journal article (peer-reviewed)abstract
- The Zwicky Transient Facility recently announced the detection of an optical transient AT2020blt at redshift z = 2.9, consistent with the afterglow of an on-axis gamma-ray burst. However, no prompt emission was observed. We analyse AT2020blt with detailed models, showing the data are best explained as the afterglow of an on-axis long gamma-ray burst, ruling out other hypotheses such as a cocoon and a low-Lorentz factor jet. We search Fermi data for prompt emission, setting deeper upper limits on the prompt emission than in the original detection paper. Together with KONUS-Wind observations, we show that the gamma-ray efficiency of AT2020blt is less than or similar to 0.3-4.5 per cent. We speculate that AT2020blt and AT2021any belong to the low-efficiency tail of long gamma-ray burst distributions that are beginning to be readily observed due to the capabilities of new observatories like the Zwicky Transient Facility.
|
|
| 8. |
- Chu, SH, et al.
(author)
-
Integration of Metabolomic and Other Omics Data in Population-Based Study Designs: An Epidemiological Perspective
- 2019
-
In: Metabolites. - : MDPI AG. - 2218-1989. ; 9:6
-
Journal article (peer-reviewed)abstract
- It is not controversial that study design considerations and challenges must be addressed when investigating the linkage between single omic measurements and human phenotypes. It follows that such considerations are just as critical, if not more so, in the context of multi-omic studies. In this review, we discuss (1) epidemiologic principles of study design, including selection of biospecimen source(s) and the implications of the timing of sample collection, in the context of a multi-omic investigation, and (2) the strengths and limitations of various techniques of data integration across multi-omic data types that may arise in population-based studies utilizing metabolomic data.
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
- Sarin, Nikhil, et al.
(author)
-
Linking the rates of neutron star binaries and short gamma-ray bursts
- 2022
-
In: Physical Review D. - : American Physical Society (APS). - 2470-0010 .- 2470-0029. ; 105:8
-
Journal article (peer-reviewed)abstract
- Short gamma-ray bursts are believed to be produced by both binary neutron star (BNS) and neutron star-black hole (NSBH) mergers. We use current estimates for the BNS and NSBH merger rates to calculate the fraction of observable short gamma-ray bursts produced through each channel. This allows us to constrain merger rates of a BNS to R-BNS = 384(-213)(+431) Gpc(-3) yr(-1) (90% credible interval), a 16% decrease in the rate uncertainties from the second Laser Interferometer Gravitational Wave Observatory (LIGO)-Virgo Gravitational-Wave Transient Catalog. Assuming a top-hat emission profile with a large Lorentz factor, we constrain the average opening angle of gamma-ray burst jets produced in BNS mergers to approximate to 15 degrees. We also measure the fraction of BNS and NSBH mergers that produce an observable short gamma-ray burst to be 0.02(-0.01)(+0.02) and 0.01 +/- 0.01, respectively, and find that greater than or similar to 40% of BNS mergers launch jets (90% confidence). We forecast constraints for future gravitational-wave detections given different modeling assumptions, including the possibility that BNS and NSBH jets are different. With 24 BNS and 55 NSBH observations, expected within six months of the LIGO-Virgo-Kamioka Gravitational Wave Detector network operating at design sensitivity, it will be possible to constrain the fraction of BNS and NSBH mergers that launch jets with 10% precision. Within a year of observations, we can determine whether the jets launched in NSBH mergers have a different structure than those launched in BNS mergers and rule out whether greater than or similar to 80% of binary neutron star mergers launch jets. We discuss the implications of future constraints on understanding the physics of short gamma-ray bursts and binary evolution.
|
|
